CLPTM1L (Cleft lip and palate transmembrane protein 1-like) has been previously shown to be overexpressed in lung cancer and is involved in regulating cisplatin sensitivity. In this study, we assessed the relationship between CLPTM1L expression and prognosis of lung cancer in patients and explored its role in regulating cell migration and invasion.
METHODS:
Immunohistochemistry was used to examine CLPTM1L expression levels on a tissue microarray containing 73 sets of human lung cancer specimens with adjacent normal tissue. The correlation between CLPTM1L expression and patient survival was analysed by the Kaplan-Meier method. In addition, CLPTM1L-knockdown lung cells were used to investigate the effect of CLPTM1L on cell migration and invasion in vitro.
RESULTS:
The results of immunohistochemical analysis showed that CLPTM1L was overexpressed in lung cancer tissues compared with adjacent normal tissues. Kaplan-Meier analyses revealed that patients with high CLPTM1L expression showed poorer survival than those with low CLPTM1L expression. In addition, in vitro studies revealed that the knockdown of CLPTM1L expression in 95-D lung cancer cells suppressed cell migration and invasion. Further, the loss of CLPTM1L resulted in decreased matrix metalloproteinase-2 (MMP-2) expression in these cells.
CONCLUSION:
Our data demonstrate that CLPTM1L overexpression can predict poor prognosis in patients with lung cancer and suggest that CLPTM1L might be associated with the regulation of cell migration and invasion.
McKayJ., HungR., GaborieauV., BoffettaP., ChabrierA. and ByrnesG., Lung cancer susceptibility locus at 5p15.33, Nat Genet40 (2008), 1404-1406.
2.
WangY., BroderickP., WebbE., WuX., VijayakrishnanJ., MatakidouA., QureshiM., DongQ., GuX., ChenW.V., SpitzM.R., EisenT., AmosC.I. and HoulstonR.S., Common 5p15.33 and 6p21.33 variants influence lung cancer risk, Nat Genet40 (2008), 1407-9.
3.
ZienolddinyS., SkaugV., LandvikN.E., RybergD., PhillipsD.H., HoulstonR. and HaugenA., The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung, Carcinogenesis30 (2009), 1368-71.
4.
LiuC., WangY., HuangH., WangC., ZhangH., KongY. and ZhangH., Association between CLPTM1L-TERT rs401681 polymorphism and pancreatic cancer risk among Chinese Han population, Tumour Biol (2014).
5.
YangX., YangB., LiB. and LiuY., Association between TERT-CLPTM1L rs401681[C] allele and NMSC cancer risk: a meta-analysis including 45,184 subjects, Arch Dermatol Res305 (2013), 49-52.
6.
ZhaoY., ChenG., SongX., ChenH., MaoY. and LuD., Fine-mapping of a region of chromosome 5p15.33 (TERT-CLPTM1L) suggests a novel locus in TERT and a CLPTM1L haplotype are associated with glioma susceptibility in a Chinese population, Int J Cancer131 (2012), 1569-76.
7.
YamamotoK., OkamotoA., IsonishiS., OchiaiK. and OhtakeY., A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis, Biochem Biophys Res Commun280 (2001), 1148-54.
8.
JamesM.A., WenW., WangY., ByersL.A., HeymachJ.V., CoombesK.R., GirardL., MinnaJ. and YouM., Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus, PLoS One7 (2012), e36116.
9.
NiZ., TaoK., ChenG., ChenQ., TangJ., LuoX., YinP. and WangX., CLPTM1L is overexpressed in lung cancer and associated with apoptosis, PLoS One7 (2012), e52598.
10.
JamesM.A., VikisH.G., TateE., RymaszewskiA.L. and YouM., CRR9/CLPTM1L regulates cell survival signaling and is required for Ras transformation and lung tumorigenesis, Cancer Res74 (2014), 1116-27.
11.
JiaJ., BosleyA.D., ThompsonA., HoskinsJ.W., CheukA., CollinsI., ParikhH., XiaoZ., YlayaK., DzyadykM., CozenW., HernandezB.Y., LynchC.F., LoncarekJ., AltekruseS.F., ZhangL., WestlakeC.J., FactorV.M., ThorgeirssonS., BamletW.R., HewittS.M., PetersenG.M., AndressonT. and AmundadottirL.T., CLPTM1L Promotes Growth and Enhances Aneuploidy in Pancreatic Cancer Cells, Cancer Res74 (2014), 2785-95.
12.
YoonS.O., ParkS.J., YunC.H. and ChungA.S., Roles of matrix metalloproteinases in tumor metastasis and angiogenesis, J Biochem Mol Biol36 (2003), 128-37.
13.
MareckoI., CvejicD., TaticS., DragutinovicV., PaunovicI. and SavinS., Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma, Cancer Biomark11 (2011), 49-58.
14.
KaramA.K., SantiskulvongC., FeketeM., ZabihS., EngC. and DorigoO., Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression, Cytoskeleton (Hoboken)67 (2010), 535-44.
15.
BjorklundM. and KoivunenE., Gelatinase-mediated migration and invasion of cancer cells, Biochim Biophys Acta1755 (2005), 37-69.
16.
TorreL.A., BrayF., SiegelR.L., FerlayJ., Lortet-TieulentJ. and JemalA., Global cancer statistics, 2012, CA Cancer J Clin65 (2015), 87-108.
17.
LouE., JohnsonM., SimaC., Gonzalez-EspinozaR., FleisherM., KrisM.G. and AzzoliC.G., Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer, Cancer Biomark14 (2014), 207-14.
18.
SubramaniamS., ThakurR.K., YadavV.K., NandaR., ChowdhuryS. and AgrawalA., Lung cancer biomarkers: State of the art, J Carcinog12 (2013), 3.
19.
LandoM., HoldenM., BergersenL.C., SvendsrudD.H., StokkeT., SundforK., GladI.K., KristensenG.B. and LyngH., Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer, PLoS Genet5 (2009), e1000719.
20.
Vazquez-MenaO., Medina-MartinezI., Juarez-TorresE., BarronV., EspinosaA., Villegas-SepulvedaN., Gomez-LagunaL., Nieto-MartinezK., OrozcoL., Roman-BasaureE., Munoz CortezS., Borges IbanezM., Venegas-VegaC., Guardado-EstradaM., Rangel-LopezA., KofmanS. and BerumenJ., Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines, PLoS One7 (2012), e32667.
21.
ZhangR., ChenX., ZhangS., ZhangX., LiT., LiuZ., WangJ., ZangW., WangY., DuY. and ZhaoG., Upregulation of miR-494 Inhibits Cell Growth and Invasion and Induces Cell Apoptosis by Targeting Cleft Lip and Palate Transmembrane 1-Like in Esophageal Squamous Cell Carcinoma, Dig Dis Sci60 (2015), 1247-55.
22.
LeeH., KimJ.S. and KimE., Fucoidan from seaweed Fucus vesiculosus inhibits migration and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways, PLoS One7 (2012), e50624.
23.
LeeY.C., LinH.H., HsuC.H., WangC.J., ChiangT.A. and ChenJ.H., Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway, Eur J Pharmacol632 (2010), 23-32.
24.
TangJ.M., HeQ.Y., GuoR.X. and ChangX.J., Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis, Lung Cancer51 (2006), 181-91.
25.
ParkJ.K., ParkS.H., SoK., BaeI.H., YooY.D. and UmH.D., ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB, Int J Oncol36 (2010), 181-92.
26.
ShuklaS., MaclennanG.T., HartmanD.J., FuP., ResnickM.I. and GuptaS., Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion, Int J Cancer121 (2007), 1424-32.
27.
DeryckeL., StoveC., Vercoutter-EdouartA.S., De WeverO., DolleL., ColpaertN., DepypereH., MichalskiJ.C. and BrackeM., The role of non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer cells, Int J Dev Biol55 (2011), 835-40.
28.
SandquistJ.C., SwensonK.I., DemaliK.A., BurridgeK. and MeansA.R., Rho kinase differentially regulates phosphorylation of nonmuscle myosin II isoforms A and B during cell rounding and migration, J Biol Chem281 (2006), 35873-83.
